» Articles » PMID: 26175878

Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation

Overview
Journal Korean J Pain
Date 2015 Jul 16
PMID 26175878
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuropathic pain is a global clinical problem; nevertheless, nerve injury treatment methods remain limited. Olanzapine has antinociceptive and anti-nueropathic properties; however, its preventive effects have not been assessed in nerve injury models.

Methods: We prepared a partial sciatic nerve ligation (Seltzer model) or sham-operated model in male Sprague-Dawley rats under isoflurane anesthesia. In a pre-treatment study, we administered olanzapine (10 mg/kg) intraperitoneally 1 h before nerve ligation. In post-treatment and dose-dependent studies, we injected 3 different doses of olanzapine intraperitoneally 1 h after nerve ligation. Mechanical allodynia was measured before and 7 days after surgery. Immunohistochemical analysis using anti-Iba-1 antibody was used to assess the effect of olanzapine at the spinal level.

Results: In the pre-treatment study, median withdrawal thresholds of the normal saline groups were significantly lower than those of the sham-operated groups; however, those of the olanzapine (10 mg/kg) and sham-operated groups were not different. In the post-treatment and dose-dependent studies, the median withdrawal thresholds of the olanzapine (2.5 mg/kg) and normal saline groups were not different; however, those of the olanzapine (10 and 50 mg/kg) groups were significantly higher than those of the normal saline groups. Olanzapine did not have a significant effect on the density of Iba-1 staining.

Conclusions: Olanzapine attenuated mechanical allodynia dose-dependently in the Seltzer model. This anti-allodynic effect of olanzapine was observed even when injected 1 h after nerve ligation. This effect of olanzapine appeared to be unrelated to microglia activation in the ipsilateral dorsal horn of the lumbar spinal cord.

Citing Articles

Response After Repeated Ketamine Injections in a Rat Model of Neuropathic Pain.

Kim N, Kim B, Lee J, Chung H, Kwon H, Kim Y Physiol Res. 2022; 71(2):297-303.

PMID: 35275700 PMC: 9150560. DOI: 10.33549/physiolres.934841.


Proof-of-Concept for the Analgesic Effect and Thermoregulatory Safety of Orally Administered Multi-Target Compound SZV 1287 in Mice: A Novel Drug Candidate for Neuropathic Pain.

Horvath A, Szentes N, Tekus V, Payrits M, Szoke E, Olah E Biomedicines. 2021; 9(7).

PMID: 34209525 PMC: 8301340. DOI: 10.3390/biomedicines9070749.

References
1.
Yawn B, Wollan P, Weingarten T, Watson J, Hooten W, Melton 3rd L . The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2010; 10(3):586-93. PMC: 2964880. DOI: 10.1111/j.1526-4637.2009.00588.x. View

2.
Kawano T, Soga T, Chi H, Eguchi S, Yamazaki F, Kumagai N . Role of the neurosteroid allopregnanolone in the hyperalgesic behavior induced by painful nerve injury in rats. J Anesth. 2011; 25(6):942-5. DOI: 10.1007/s00540-011-1216-2. View

3.
Silberstein S, Peres M, Hopkins M, Shechter A, Young W, Rozen T . Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002; 42(6):515-8. DOI: 10.1046/j.1526-4610.2002.02126.x. View

4.
Gorski E, Willis K . Report of three case studies with olanzapine for chronic pain. J Pain. 2003; 4(3):166-8. DOI: 10.1054/jpai.2003.438. View

5.
Moini Zanjani T, Ameli H, Labibi F, Sedaghat K, Sabetkasaei M . The Attenuation of Pain Behavior and Serum COX-2 Concentration by Curcumin in a Rat Model of Neuropathic Pain. Korean J Pain. 2014; 27(3):246-52. PMC: 4099237. DOI: 10.3344/kjp.2014.27.3.246. View